Yahoo
NasdaqGS - Delayed Quote USD

Apnimed, Inc. (APMD)

15.10 +0.94 (+6.64%)
At close: November 6 at 4:00:01 PM EST
15.10 -0.01 (-0.10%)
After hours: November 6 at 4:01:21 PM EST
Chart Range Bar
Loading chart for APMD
  • Previous Close 14.16
  • Open 14.26
  • Bid 15.05 x 100
  • Ask 18.07 x 200
  • Day's Range 14.11 - 15.40
  • 52 Week Range 13.88 - 35.29
  • Volume 225,337
  • Avg. Volume 469,156
  • Market Cap (intraday) 628.625M
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 2.09
  • EPS (TTM) 7.22
  • Earnings Date (est.) Nov 11, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 50.33
  • Zacks Rating Neutral

Apnimed, Inc. operates as a clinical pharmaceutical company that develops and manufactures novel oral therapies that address the neurobiology of sleep-related breathing diseases in global markets. It offers AD109, an oral therapy designed to treat obstructive sleep apnea (OSA) by targeting the underlying neuromuscular dysfunction. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

apnimed.com

81

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 11/6/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

APMD
31.36%
S&P 500 (^GSPC)
7.76%

1-Year Return

APMD
31.36%
S&P 500 (^GSPC)
9.77%

3-Year Return

APMD
31.36%
S&P 500 (^GSPC)
68.96%

5-Year Return

APMD
31.36%
S&P 500 (^GSPC)
57.04%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 12.08M
Earnings 125.94M
Profit Margin 1,042.51%

Q2

FY26

0
20M
40M
60M
80M
100M
120M
1042.5%

Analyst Insights

View More

Analyst Price Targets

41.00
50.33 Average
15.10 Current
60.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 8/25/2026
Analyst LifeSci Capital
Rating Action Initiated
Rating Outperform
Price Action Announces
Price Target 50

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    142.10%

  • Return on Assets (ttm)

    --

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    115.12M

  • Net Income Avi to Common (ttm)

    170.74M

  • Diluted EPS (ttm)

    7.22

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    172.8M

  • Total Debt/Equity (mrq)

    129.57%

  • Levered Free Cash Flow (ttm)

    --

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: